Presenting symptoms in children with neurofibromatosis type 2.


Journal

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227

Informations de publication

Date de publication:
10 2020
Historique:
received: 10 05 2020
accepted: 04 06 2020
pubmed: 17 6 2020
medline: 22 6 2021
entrez: 16 6 2020
Statut: ppublish

Résumé

The hallmark of neurofibromatosis type 2 (NF2) is the presence of bilateral vestibular schwannomas (VS) which however have not yet developed or grown to large size in children and young adolescents. Therefore, early diagnosis in pediatric patients without family history of NF2 has to be made by signs and symptoms not related to VS which will be reviewed in this study. A total of 70 children diagnosed for NF2 at an age of < 18 years were identified from our patient cohort. Age and symptoms, signs and pathology at symptom onset, age at NF2 diagnosis and symptoms leading to diagnosis as well as genetic findings were retrospectively reviewed. The average age at symptom/sign onset was 8 ± 6 (range 0-17) years and 11 ± 5 (range 1-17) years at time of diagnosis. Fifteen children had a positive family history and were diagnosed upon additional clinical symptoms. The most frequent first presenting symptom/signs were ophthalmological abnormalities (49%), followed by cutaneous features (40%), non-VS-related neurological deficits (33%), and symptoms attributable to VS (21%). VS were not only the most common symptomatic neoplasm but also the most frequent pathological evidence for the diagnosis (72%). In 42 patients with available genetic testing results, pathogenic mutations were most frequently identified (n = 27). The presenting symptoms in NF2 children appear "unspecific" or less specific for classical NF2 compared with adult NF2 patients, posing a challenge particularly for cases without family history. In children, ophthalmological and cutaneous features should raise clinical suspicion for NF2 and referral to an NF2 specialized center is recommended.

Identifiants

pubmed: 32537663
doi: 10.1007/s00381-020-04729-w
pii: 10.1007/s00381-020-04729-w
pmc: PMC7575472
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2463-2470

Références

Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93–97
doi: 10.1097/00129492-200501000-00016
Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S, Lalloo F (2009) Birth incidence and prevalence of tumour prone syndromes: estimates from UK genetic family register service. AM J Med Gen 152A:327–332
doi: 10.1002/ajmg.a.33139
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:826
doi: 10.1016/0092-8674(93)90501-G
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, Jong P, Parry D, Eldrige R, Aurias A, Delattre O, Thomas G (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515–521
doi: 10.1038/363515a0
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986
doi: 10.1016/S0140-6736(09)60259-2
Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM (1993) Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92–96
pubmed: 8355853
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618
pubmed: 1484939
Ruggieri M, Pratico AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, Romano A, Chiarenza A, Muglia M, Polizzi A, Evans DG (2016) Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital 36:345–367
pubmed: 27958595 pmcid: 5225790
Anand G, Vasallo G, Spanou M, Thomas S, Pike M, Kariyawasam DS, Mehta S, Parry A, Durie-Gair J, Nicholson J, Lascelles K, Everett V, Gibbon FM, Jarvis N, Elston J, Evans DG, Halliday D (2018) Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Arch Dis Child 103:463–469
doi: 10.1136/archdischild-2017-313154
Choi JW, Lee JY, Phi JH, Wang KC, Chung HT, Paek SH, Kim DG, Park SH, Kim SK (2014) Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. J Neurosurg Pediatr 13:650–657
doi: 10.3171/2014.3.PEDS13455
Evans DG, Birch JM, Ramsden RT (1999) Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496–499
doi: 10.1136/adc.81.6.496
Matsuo M, Ohno K, Ohtsuka F (2014) Characterization of early onset neurofibromatosis type 2. Brain Dev 36:148–152
doi: 10.1016/j.braindev.2013.01.007
Ruggieri M, Gabriele AL, Polizzi A, Salpietro V, Nicita F, Pavone P, Platania N, Milone P, Distefano A, Privitera G, Belfiore G, Granata F, Caltabiano R, Albanese V, Pavone L, Quattrone A (2013) Natural history of neurofibromatosis type 2 with onset before the age of 1 year. Neurogenetics 14:89–98
doi: 10.1007/s10048-013-0354-0
Gugel I, Mautner VF, Kluwe L, Tatagiba MS, Schuhmann MU (2018) Cerebrovascular insult as presenting symptom of neurofibromatosis type 2 in children, adolescents, and young adults. Front Neurol 9:733
doi: 10.3389/fneur.2018.00733
Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DG (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 13:576–581
doi: 10.1097/GIM.0b013e318211faa9
Gugel I, Grimm F, Liebsch M, Zipfel J, Teuber C, Kluwe L, Mautner VF, Tatagiba M, Schuhmann MU (2019) Impact of surgery on long-term results of hearing in neurofibromatosis type-2 associated vestibular schwannomas. Cancers 11
Gaudioso C, Listernick R, Fisher MJ, Campen CJ, Paz A, Gutmann DH (2019) Neurofibromatosis 2 in children presenting during the first decade of life. Neurology 93:e964–e967
doi: 10.1212/WNL.0000000000008065
Dudley RWR, Torok MR, Randall S, Beland B, Handler MH, Mulcahy-Levy JM, Liu AK, Hankinson TC (2018) Pediatric versus adult meningioma: comparison of epidemiology, treatments, and outcomes using the Surveillance, Epidemiology, and End Results database. J Neurooncol 137:621–629
doi: 10.1007/s11060-018-2756-1
MacCollin M, Mautner VF (1998) The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 5:243–252
doi: 10.1016/S1071-9091(98)80003-X
Kluwe L, Mautner VF (1998) Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051–2055
doi: 10.1093/hmg/7.13.2051
Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, Scott HS, Tabori U (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res 23:e54–e61
doi: 10.1158/1078-0432.CCR-17-0590

Auteurs

Isabel Gugel (I)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany. isabel.gugel@med.uni-tuebingen.de.
Centre of Neurofibromatosis, Centre of Rare Disease, University Hospital Tübingen, Tübingen, Germany. isabel.gugel@med.uni-tuebingen.de.

Florian Grimm (F)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.

Christian Teuber (C)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.

Julian Zipfel (J)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Centre of Neurofibromatosis, Centre of Rare Disease, University Hospital Tübingen, Tübingen, Germany.
Division of Pediatric Neurosurgery, University Hospital Tübingen, Tübingen, Germany.

Marcos Tatagiba (M)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Centre of Neurofibromatosis, Centre of Rare Disease, University Hospital Tübingen, Tübingen, Germany.

Victor-Felix Mautner (VF)

Centre of Neurofibromatosis, Centre of Rare Disease, University Hospital Tübingen, Tübingen, Germany.
Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Martin Ulrich Schuhmann (MU)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Centre of Neurofibromatosis, Centre of Rare Disease, University Hospital Tübingen, Tübingen, Germany.
Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lan Kluwe (L)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH